Jonathan Rockoff
Verified
(He/Him)
As seen in:
The Wall Street Journal,
MSN,
The Wall Street Journal (China),
The Wall Street Journal (Japan),
Yahoo Finance,
MarketWatch,
The Toronto Star,
Flipboard,
Mint,
Fox Business,
Business Standard
and
Covers:
Business news, including airlines, agriculture, autos, consumer goods, healthcare, manufacturing, shipping and retail
Deputy Coverage Chief, Health & Science and Health Business editor at the @WSJ. Email me at jonathan.rockoff@wsj.com
Articles by Jonathan Rockoff
A Guide to the Biggest Winners From the SpaceX IPO
Elon Musk isn’t the only big winner from the SpaceX SPCX 17.24%increase; green up pointing triangle IPO. From longtime executives to short-term employees, college endowments and venture-capital firms, all stand to benefit from their stakes in the rocket maker. Here’s a look at some of these winners. Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
盘点SpaceX IPO最大赢家们
埃隆·马斯克(Elon Musk)并不是SpaceX IPO的唯一大赢家。凭借手中持有的这家火箭制造商股份，从资深高管到短期员工，再到大学捐赠基金与风投机构，各路投资者都将获利丰厚。 以下是部分赢家一览 内部人士 创始人兼首席执行官马斯克是SpaceX最大的单一股东。他拥有约40%的股份，这让他在账面上跃升为全球首位万亿富翁。看看他的财富是如何积累的。 Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
A guide to the biggest winners from the SpaceX IPO
; ; ; ; ; ; Continue reading More for You ; ; ; ; Continue reading More for You
Microsoft Cares About Your Privacy Eli Lilly strikes deal for cancer biotech
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised advertising and content, advertising and content measurement, audience research and services development. List of partners (vendors) Lauren Thomas, Jonathan D.
Exclusive | Merck No Longer in Talks to Buy Revolution Medicines
Merck MRK -0.92 %decrease; red down pointing triangle is no longer in discussions to buy biotech Revolution Medicines RVMD -0.99 %decrease; red down pointing triangle , according to people familiar with the matter. Merck had recently been in talks to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.
Merck in talks to buy Revolution Medicines for around $30 billion
Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people familiar with the matter.A deal for the cancer-drug biotech could come as soon as later this month, the people said, cautioning the talks could still fall apart or another suitor could prevail.Merck has been discussing a deal valued between $28 billion and $32 billion, the people added.The Financial Times reported Thursday that Merck was discussing a deal with Revolution...
Eli Lilly nears deal for biotech Ventyx
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for around $1 billion, according to people familiar with the matter.A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could come as soon as Wednesday, the people said.The detailsVentyx, of San Diego, had a market value of a little over $500 million as of Tuesday afternoon.
Pfizer and Metsera Reach Deal Expected to Top $10 Billion
Pfizer has agreed to buy the weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting Novo Nordisk following a heated bidding war. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday. In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.
Pfizer Preps Improved Offer in Metsera Bidding War
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.New York-based Pfizer is making plans to deliver a fresh bid Wednesday, according to people familiar with the matter, ahead of a deadline it has to respond to Novo Nordisks latest proposal.Under the terms of its existing merger agreement with Metsera, Pfizers next likely step is to match Novo Nordisks offer, one of the people said.Metsera...
Pfizer's Pricing Deal Went Down to the Wire
Try GOLD - Free The Wall Street Journal | October 04, 2025 Over a weekend in late September, the team of Pfizer officials working with the Trump administration on drug prices got a message: Clear your schedules. This story is from the October 04, 2025 edition of The Wall Street Journal. Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers. Already a subscriber? Sign In
Inside Pfizer’s drug-pricing deal with the Trump administration
Global Summary Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla. This is a Mint Premium article gifted to you. Subscribe to enjoy similar stories. Over a weekend in late September, the team of Pfizer officials working with the Trump administration on drug prices got a message: Clear your schedules. Negotiations were reaching a tipping point.
Exclusive | Trump Administration Weighing Major Cuts to Funding for Domestic HIV Prevention
The discussions come as the Trump administration is preparing for deep cuts of personnel at the Centers for Disease Control and Prevention, part of a reorganization of the agency, people familiar with the planning said. The cuts and reorganization would take advantage of a weakness of the agency’s legal underpinnings: No single law outlines its purposes and authorizes its many programs. The CDC has a department dedicated to the prevention of HIV and other infectious diseases.
トランプ政権、HIV感染対策費の大幅削減検討
米厚生省は、国内のHIV（ヒト免疫不全ウイルス）感染予防関連の連邦政府予算を大幅に削減することを検討している。事情に詳しい関係者らが明らかにした。 削減計画は一両日中にも発表される見通しだが、最終決定でなく、撤回または修正される可能性もあると関係者らは述べている。トランプ政権は疾病対策センター（CDC）の人員の大幅削減についても準備を進めており、予算削減も再編の一環だという。 Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Exclusive | Trump Administration Weighing Major Cuts to Funding for Domestic HIV Prevention
March 18, 2025 3:57 pm ET The Health and Human Services Department is weighing plans to drastically cut the federal government’s funding for domestic HIV prevention, according to people familiar with the matter. The plans could be announced as soon as within a day, the people said, but they haven’t been finalized and could be pulled back or adjusted. Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Johns Hopkins Slashes More Than 2,000 Jobs Due to USAID Cuts
March 13, 2025 5:12 pm ET Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Pharma, Long Criticized by RFK Jr., Looks for Ways to Work With Him
President-elect Donald Trump’s selection of Robert F. Kennedy Jr. to be Health and Human Services secretary was a worst case-scenario for drugmakers. Now, they will try to make the best of it. Kennedy has supported discredited theories that link vaccines to autism and antidepressants to school shootings. If confirmed as HHS secretary, he could push to end drug advertising on television and liability protections for vaccine makers.
Pharma, Long Criticized by RFK Jr., Looks for Ways to Work With Him
None of the policy changes are on the wish lists of drugmakers. Health stocks, including Pfizer, GSK and Novo Nordisk, dropped on Friday. Moderna and BioNTech fell more than 4%. The nomination “could have broad-reaching implications for the entire biopharma sector and many individual” companies, RBC analyst Brian Abrahams wrote to investors. Industry officials say there is little they can do to stop Kennedy’s ascension, though some hold out hope the Senate will reject the nomination.
Exclusive | Two Brothers, a Big Biotech Bet and an $8 Billion Payout
A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by brothers Felix and Julian Baker , had in 2003 invested in Seagen, a developer of next-generation cancer treatments. Pfizer bought the company for $43 billion last year.
WSJ News Exclusive | Bristol Myers to Buy Karuna Therapeutics for $14 Billion
Drugmaker Squibb reached a deal to buy neuroscience-drug developer for $14 billion. Under the terms, Bristol would pay $330 a share in cash for Karuna and its experimental schizophrenia drug now up for U.S. government approval. Bristol expects the deal, which includes $1.3 billion in cash that Karuna has on hand, would close in the first half of next year.
WSJ News Exclusive | Pfizer Prices Covid Drug Paxlovid at $1,400 for a Five-Day Course
will price a course of its Covid-19 drug Paxlovid at nearly $1,400 when commercial sales begin later this year, more than double what the U.S. government has paid. Pfizer told the pharmacies and clinics that will dispense Paxlovid, in a letter dated Wednesday that was viewed by The Wall Street Journal, that a five-day course of the antiviral will list for $1,390. The U.S. government had paid $529.
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Roivant Sciences, a biotech company started by Republican presidential candidate Vivek Ramaswamy, is in talks to sell an experimental drug for a debilitating stomach disease to Roche Holding, in a deal that could be valued at more than $7 billion. Sale of the drug, for conditions known as ulcerative colitis and Crohn’s disease, could be announced in the coming days, according to people familiar with the matter.
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Roivant Sciences, a biotech company started by Republican presidential candidate Vivek Ramaswamy, is nearing a deal to sell an experimental drug for a debilitating stomach disease to Roche Holding in a deal that could be valued at more than $7 billion. Sale of the drug, for conditions known as ulcerative colitis and Crohn’s disease, could be announced in the coming days, according to people familiar with the matter.
WSJ News Exclusive | Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Roivant Sciences, a biotech company started by Republican presidential candidate Vivek Ramaswamy, is in talks to sell an experimental drug for a debilitating stomach disease to Holding, in a deal that could be valued at more than $7 billion. Sale of the drug, for conditions known as ulcerative colitis and Crohn’s disease, could be announced in the coming days, according to people familiar with the matter.
FTC否决Illumina以70亿美元收购癌症早筛公司Grail的交易
联邦贸易委员会(FTC)否决了Illumina Inc. (ILMN)以70亿美元收购癌症检测开发商Grail Inc.的交易，称这笔交易将损害诊断医学新领域之一的竞争。 FTC周一命令Illumina撤销拟议中的合并，推翻了一名行政法法官此前支持这家大型医疗检测公司的裁决。 ...
FTC Rejects Illumina’s $7 Billion Deal for Cancer-Test Developer Grail Original
The Federal Trade Commission rejected Illumina Inc.’s $7 billion deal for cancer-test developer Grail Inc., saying that going ahead would hurt competition in one of the new frontiers of diagnostic medicine. The FTC on Monday ordered Illumina to unwind the proposed merger, reversing an administrative law judge’s ruling that supported the big medical testing company.
FTC Rejects Illuminas $7 Billion Deal for Cancer-Test Developer Grail
The agency said the combination would hurt competition for cancer-detection tests while raising prices
فايزر تستحود على شركة أدوية لعلاج السرطان مقابل 43 مليار دولار
وافقت شركة الأدوية العملاقة "فايزر" على دفع 43 مليار دولار مقابل الاستحواذ على شركة صناعة الأدوية "سيغين" للتكنولوجيا الحيوية وفئاتها الواعدة من عقاقير السرطان المستهدفة. وقالت الشركة يوم الإثنين، إنه بموجب الشروط، ستدفع فايزر 229 دولارًا للسهم، وتتوقع الشركتان أن تنتهي الصفقة في أواخر هذا العام أو أوائل العام المقبل. وكانت شركة فايزر تبحث عن عمليات استحواذ لمساعدتها على تعويض الخسائر في المبيعات المتوقعة حيث تفقد بعض الأدوية الأكثر مبيعًا حماية براءات الاختراع في السنوات العديدة القادمة.
Pfizer Agrees to Buy Seagen for $43 Billion
Pfizer has been looking for acquisitions to help it offset losses in sales. Pfizer Inc. has agreed to pay $43 billion for biotech Seagen Inc. and its pioneering class of targeted cancer drugs. Under the terms, Pfizer would pay $229 a share cash, the drugmaker said Monday. The companies expect the deal to close late this year or early next year.
Pfizer in talks to acquire Seagen in deal likely valued at more than $30B
Pfizer Inc. is in talks to acquire biotech Seagen Inc., according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies. The talks are at an early stage, and there is no guarantee there will be a deal, the people said. A number of hurdles would need to be overcome, including the potential for a stringent antitrust review of any proposal.
WSJ News Exclusive | Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion
Pfizer Inc. is in talks to acquire biotech Seagen Inc., according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies. The talks are at an early stage and there is no guarantee there will be a deal, the people said. A number of hurdles would need to be overcome, including the potential for a stringent antitrust review of any proposal.
فايزر تدرس التوسع في أدوية السرطان بالاستحواذ على سيغين
تجري شركة فايزر للأدوية محادثات للاستحواذ على شركة سيغين للتكنولوجيا الحيوية وفقاً لأشخاص مطلعين على الأمر، وفي حال اتمام الصفقة ستكون أحدث صفقة لشركة أدوية كبيرة وستساعد في إضافة فئة واعدة من أدوية السرطان التي تستهدف الشركة تطويرها. وقال أشخاص مطلعين لصحيفة وول ستريت جورنال "أن المحادثات لا تزال في مرحلة مبكرة، وأنه ليس هناك ما يضمن التوصل إلى اتفاق، حيث يتطلب ذلك التغلب على عدد من العقبات".
米ファイザー、シージェンの買収に向け協議
米製薬大手ファイザーがバイオテク企業の米シージェンの買収に向け、初期段階の交渉を行っていることが分かった。事情に詳しい関係者らが明らかにした。 関係者らによれば、交渉はまだ初期の段階にあるため、合意がまとまる保証はない。またどのような案であっても反トラスト（独占禁止）を巡る厳しいレビューが実施される可能性があるなど、複数のハードルが残っているという。 ...
Pfizer Is in Early-Stage Talks to Acquire Seagen
1 day ago Earlier this month, Texas’s Republican Attorney General Ken Paxton filed a lawsuit claiming that the $1.7 trillion spending law that keeps most of the federal government — including the US military — operating through September of 2023 is unconstitutional. Paxton’s claims in Texas v. Garland, which …
WSJ News Exclusive | Pfizer in Early-Stage Talks to Acquire Seagen
Pfizer Inc. is in talks to acquire biotech Seagen Inc, according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies. The talks are at an early stage and there is no guarantee there will be a deal, the people said. A number of hurdles would need to be overcome, including the potential for a stringent antitrust review of any proposal.
Pfizer eyes takeover of biotech Seagen, at value of more than $30 billion
Pfizer Inc. is in talks to acquire biotech Seagen Inc. , according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies. The talks are at an early stage and there is no guarantee there will be a deal, the people said. A number of hurdles would need to be overcome, including the potential for a stringent antitrust review of any proposal.
Live Question & Answer Event - Peter Loftus on His New Book, ‘The Messenger' - WSJ.com
LIVE Q&A | Begins 1:00 PM ET FEBRUARY 7, 2023 Peter Loftus on His New Book, ‘The Messenger' In his new book, author and WSJ reporter Peter Loftus describes how Moderna went from a beleaguered biotech firm to developing one of the first Covid-19 vaccines. The author sits down with Jonathan Rockoff, health business editor at The Wall Street Journal, for a behind-the-scenes glimpse into the making of the book.
Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer
Under the terms, Merck said Monday it will pay $36 a share cash for Imago, which is developing drugs to treat bone-marrow diseases. Merck said it expected the deal to close during the first quarter next year. Merck has been seeking deals to add fast-growing products and promising drugs in development as it prepares for the patent expiration on its top-selling product, a cancer immunotherapy called Keytruda. Keytruda had $17.2 billion of Merck’s $48.7 billion in worldwide sales last year.
Moderna’s CEO on Its New Covid-19 Booster, Prospects for Cancer Vaccines
Life What’s Ahead for Education & Learning In the latest issue, The Future of Everything explores what’s ahead for education, from the pandemic’s long-lasting impact on a generation of students to new roles for tech in teaching reading.
Pfizer agrees to $5.4B deal for Global Blood Therapeutics
Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. for $5.4 billion, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease. Pfizer said Monday it would pay $68.50 a share in cash for Global Blood Therapeutics, which has one of the few approved treatments for sickle-cell disease. The Wall Street Journal reported Friday that the companies were in advanced talks.
Pfizer Reaches $5.4 Billion Deal for Global Blood Therapeutics
Pfizer Inc. has agreed to buy Global Blood Therapeutics Inc. for $5.4 billion, according to people familiar with the matter, in a deal that would give the big drugmaker a foothold in the treatment of sickle-cell disease. Pfizer would pay $68.50 a share in cash for Global Blood Therapeutics, which has one of the few approved treatments for sickle-cell disease, the people said. The companies are expected to announce the deal Monday morning.
辉瑞就以约50亿美元收购Global Blood Therapeutics进行深入谈判
辉瑞公司(Pfizer Inc., PFE)正就以约50亿美元收购Global Blood Therapeutics Inc. (GBT, 简称GBT)进行深入谈判，后者是最近获批的一种治疗镰状细胞病的药物制造商，这是这家药物巨头加强其产品组合和研发药品的最新举措。 ...
Pfizer in advanced talks to buy Global Blood Therapeutics for about $5 billion
Pfizer Inc. is in advanced talks to buy Global Blood Therapeutics Inc., the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline. Pfizer is aiming to seal a deal for GBT in the coming days, according to people familiar with the matter. The situation is still fluid, and other suitors are still in the mix, some of the people said. GBT announces its second-quarter results Monday.
WSJ News Exclusive | Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer Inc. PFE -0.28%▼ is in advanced talks to buy Global Blood Therapeutics Inc., GBT 9.56%▲ the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline. Pfizer is aiming to seal a deal for GBT in the coming days, according to people familiar with the matter. The situation is still fluid and other suitors are still in the mix, some of the people said. GBT announces its second-quarter results Monday.
Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say
Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to people familiar with the matter. The Wall Street Journal reported earlier this month that Merck MRK aimed to agree on a purchase of the cancer biotech within a few weeks, a plan that has since been delayed, the people said. The...
Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say
Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to people familiar with the matter. The Wall Street Journal reported earlier this month that Merck MRK, +1.15% aimed to agree on a purchase of the cancer biotech within a few weeks, a plan that has since been delayed, the people said.
FDA Fully Approves Pfizer’s Covid Vaccine for Adolescents
Pfizer’s Covid-19 vaccine has been available to 12 to 15 years old since May 2021 on an emergency basis. Federal health regulators fully approved the Covid-19 vaccine from Pfizer Inc. and partner BioNTech SE in children 12 to 15 years old. The companies said Friday they had received the Food and Drug Administration’s approval for the shot, which has been available to the children since May 2021 on an emergency basis.
WSJ News Exclusive | Merck Is in Advanced Talks to Buy Seagen
Merck & Co. is in advanced talks to acquire Seagen Inc. and is aiming to finalize a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that could be worth roughly $40 billion or more. The companies are discussing a price for Seagen above $200 a share and are seeking to seal a deal on or before the announcement of Merck’s second fiscal-quarter earnings, set for July 28, the people said. Seagen’s stock closed at $175.13 on Wednesday.
Pfizer’s Omicron-Targeting Covid-19 Vaccines Generate Stronger Immune Response
By Jared S. Hopkins and Jonathan D. Rockoff June 25, 2022 10:07 am ET Pfizer Inc. and BioNTech SE vaccines modified to target the Omicron variant produced a significantly larger immune response than the companies’ currently available vaccine in a study, they said. (More to Come)
WSJ News Exclusive | Merck Pushes Forward With Potential Deal for Seagen
By Dana Cimilluca, Cara Lombardo and Jonathan D. Rockoff June 23, 2022 7:25 pm ET Merck & Co. is pushing forward with a potential deal for biotech Seagen according to people familiar with the matter, in what would be one of the largest takeovers of the year. The Wall Street Journal reported last week that Merck was in talks to buy Seagen, which would beef up the pharmaceutical giant’s cancer-drug portfolio, but that no agreement was imminent.
FDA Advisers Raise Doubts About Amylyx’s Experimental ALS Drug
The FDA has faced criticism that it has relaxed its standards and isn’t rigorously scrutinizing some experimental drugs. Neuroscience experts advising the Food and Drug Administration found that a study didn’t provide sufficient evidence that Amylyx Pharmaceuticals Inc.’s experimental amyotrophic lateral sclerosis drug works.
Show More
loading
Actions
Get in touch with Jonathan
Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack